SIC
ACXP icon

Salem Investment Counselors’s Acurx Pharmaceuticals ACXP Stock Holding History

Salem Investment Counselors’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5
Closed -$265 – 1101
2023
Q2 		$265 Buy
+5
New +$298 ﹤0.01% 1107

Other funds holding ACXP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Salem Investment Counselors's ACXP Position: Q3 2023 in Review

Salem Investment Counselors sold out of Acurx Pharmaceuticals (ACXP) in Q3 2023, closing a stake of 5 shares — an estimated $265 sold.

Salem Investment Counselors first reported a position in ACXP in Q2 2023 and held it in 1 quarter. The position peaked at $265 in Q2 2023. 18 funds tracked by Wall St. Rank hold ACXP as of Q3 2023.

  • Salem Investment Counselors reported no remaining Acurx Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Salem Investment Counselors sold 5 Acurx Pharmaceuticals shares in Q3 2023, an estimated $265.
  • Salem Investment Counselors first reported a position in Acurx Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Salem Investment Counselors's Acurx Pharmaceuticals position peaked at $265 in Q2 2023.
  • 18 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2023.

Based on Salem Investment Counselors's 13F filing for Q3 2023, filed 4 Oct 2023.